| Date | Form | Description | Docs | XBRL | Pages |
| 01/12/26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
|
38 |
| 01/10/25 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
41 |
| 01/16/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
46 |
| 01/04/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
40 |
| 01/04/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
63 |
| 01/07/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
77 |
| 01/10/20 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
110 | |
| 01/09/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
128 |
| 01/11/19 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
95 |
| 01/09/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
148 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...